|
LCORL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.79499999999988E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.06199999969381E-07 |
| Normal-vs-Stage2 |
1.753980E-04 |
| Normal-vs-Stage3 |
2.32330000016212E-07 |
| Normal-vs-Stage4 |
2.575900E-04 |
| Stage1-vs-Stage2 |
9.161400E-01 |
| Stage1-vs-Stage3 |
5.430300E-02 |
| Stage1-vs-Stage4 |
8.202000E-01 |
| Stage2-vs-Stage3 |
1.967760E-01 |
| Stage2-vs-Stage4 |
9.217000E-01 |
| Stage3-vs-Stage4 |
2.566400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11379999667705E-08 |
| Normal-vs-AfricanAmerican |
5.482000E-02 |
| Normal-vs-Asian |
3.99529999994819E-06 |
| Caucasian-vs-AfricanAmerican |
1.513790E-01 |
| Caucasian-vs-Asian |
6.059800E-01 |
| AfricanAmerican-vs-Asian |
1.783380E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.47139999995272E-06 |
| Normal-vs-Female |
3.33439999999907E-06 |
| Male-vs-Female |
9.878200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.56430000000296E-05 |
| Normal-vs-Age(41-60Yrs) |
1.05319999998965E-06 |
| Normal-vs-Age(61-80Yrs) |
1.66570000004196E-06 |
| Normal-vs-Age(81-100Yrs) |
3.438300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.593170E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.361600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.095000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.526000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.554200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.884600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.333800E-02 |
| Classical-VS-Follicular |
7.737200E-01 |
| Classical-VS-Other |
4.082800E-01 |
| Classical-VS-Normal |
5.94029999999579E-05 |
| Tall-VS-Follicular |
8.059800E-02 |
| Tall-VS-Other |
8.253000E-01 |
| Tall-VS-Normal |
4.18650000000298E-07 |
| Follicular-VS-Other |
4.486800E-01 |
| Follicular-VS-Normal |
1.015570E-04 |
| Other-VS-Normal |
2.004200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.47910000306106E-08 |
| Normal-vs-N1 |
3.80549999999813E-05 |
| N0-vs-N1 |
8.569200E-01 |
|
|
